

Alzheimer's Disease (AD)

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Trial Status
Recruiting

Trial Runs In
8 Countries

Trial Identifier
NCT07177352 WP45722

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

Trial Summary:

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT07177352 WP45722
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
#50 Years & # 90 Years

Healthy Volunteers
No

Inclusion Criteria:

- Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

Exclusion Criteria:

- Dependency in basic activities of daily living (bADLs) due to cognitive impairment
- Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)

ForPatients

by Roche

- Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
- History of severe, clinically significant central nervous system trauma
- Any serious medical condition that precludes a participant's safe participation and completion of a clinical study